Novartis (NVS.US) Q3 revenue increased 4% year-over-year; long-term pipeline impairment dragged down net profit

According to Zhihui Finance APP, Novartis (NVS.US) released its financial report for the third quarter of 2026 on Tuesday. The company's net sales for the quarter were $14.522 billion, an increase of 4% year-on-year (up 4% at constant exchange rates as well), which did not meet market expectations; core operating profit was $6.036 billion, up 11% year-on-year; core earnings per share were $2.46, an increase of 9% year-on-year, beating market expectations. Due to impairments in the R&D pipeline and increased provisions, net profit under IFRS was $1.196 billion, a year-on-year decrease of 70%, with earnings per share of $0.63.